Dr. Melinda Lee Telli, MD

Dr. Telli practices at Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University.

Dr. Telli's NPI, 1932135290, was assigned on June 25, 2006. Dr. Telli graduated from George Washington University School of Medicine and Health Sciences in 2002. Dr. Telli's California license number on file is A84689.

Dr. Telli's primary practice is Stanford Hospital at 300 Pasteur Drive, at 300 Pasteur Drive, Stanford, CA 94305 in Santa Clara County. The practice phone is (650) 723-4000.

Dr. Telli's primary practice is Stanford Hospital at 300 Pasteur Drive in Stanford, California, part of Stanford University. Dr. Telli is also affiliated with Stanford Health Care Tri-Valley. The medical group on file is Stanford Health Care. Dmand AI also links Dr. Telli to 1 more hospital and 1 medical group, each named with a free account. Dr. Telli's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Telli practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Telli's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Telli is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Telli's licenses on file in 2 states: California and Florida.

Dmand AI lists breast cancer, lung cancer and lymphoma among the conditions Dr. Telli treats.

CMS data shows 344 Medicare services from Dr. Telli across 5 procedure codes in 2024, for 107 Medicare patients. Medicare paid $43,035 for them.

CMS counts 107 Medicare patients who saw Dr. Telli in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have cancer, and 68% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Telli's median patient age at 57, with 95% women.

In 2024, Dr. Telli wrote 125 Medicare Part D claims for 37 patients. 85% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $323 in total drug cost. In 2021, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Telli for performance year 2024, reported as part of a group. Dr. Telli accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Telli as offering telehealth.

Dmand AI links 119 papers to Dr. Telli, published from 2008 to 2025. 2018 was the busiest year, with 12. The most frequent topics are Breast Neoplasms, Triple Negative Breast Neoplasms and Antineoplastic Agents. Dr. Telli has published most often in J Natl Compr Canc Netw. Dr. Telli's most frequent co-authors are James Matthew Ford, MD, Sharon M. Giordano, MD, MPH and William J. Gradishar, MD.

Dmand AI links Dr. Telli to 9 clinical trials, 6 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Carcinoma, Intraductal, Noninfiltrating. Stanford University sponsors the most, 2. Open Payments lists research payments to Dr. Telli that name 1 trial.

CMS Open Payments shows 252 general payments to Dr. Telli from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 76% of the total. Merck Sharp & Dohme Corporation paid the most, $38,485. It also lists 29 research payments totaling $34,757 from 2016 to 2025, naming 1 clinical trial.

Dmand AI lists 1 award for Dr. Telli, most recently CMS Stage 1 EHR in 2013.

Dr. Telli graduated from George Washington University School of Medicine and Health Sciences in 2002. Dr. Telli is a member of AACR and ASCO.

Dr. Telli is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.